In the IMmotion151 Phase III trial, bevacizumab plus atezolizumab improved PFS compared with sunitinib in the intention-to-treat population of previously untreated patients with RCC unselected for PD-L1 expression [25]. This evidence concerns the gene CD274 and renal cell carcinoma.